Ensysce Biosciences, Inc.
ENSC
NASDAQ·Healthcare·Biotechnology·Mkt cap $7.0M
$0.40
▼ -3.85%
P/E
—
Mkt Cap
$7.0M
52-Wk Range
$0.23–$2.75
52-Week Range
$0.23 - $2.75
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 83.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary prodrug technology platforms (TAAP and MPAR) with patent protection
- First-mover advantage in abuse-resistant opioid formulations addressing regulatory demands
- Diversified pipeline across multiple therapeutic areas and patient populations
- Strategic positioning in high-impact public health markets with strong regulatory tailwinds
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
Phase II clinical trial progression of lead candidate PF614 and potential FDA approval pathway
Value
Valuation data unavailable
Momentum
Hot
+40.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ENSC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 13, 2026
Reported EPS of -$0.20 vs -$0.50 consensus (+60.0% surprise). Revenue of $1.2M vs $1.2M expected (-3.0%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+60.0%
Revenue trend · last 8Q
—
—
+332%
+654%
-86%
+44%
-27%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.4M
$1.3M
$1.3M
$1.4M
$493.1K
$1.9M
$961.0K
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ENSC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related